After months of reporting by Rolling Stone, a trial declared ‘unethical' by WHO will not move forward ...

The Hepatitis B Foundation notes that there’s still no complete cure for hepatitis B. It advises regular checkups with a ...

Oct 20 (Reuters) - The US FDA said on Tuesday it had approved British drugmaker GSK's hepatitis B drug Hibsago, allowing ...

Infants are particularly vulnerable to hepatitis B.

By Nancy Lapid Oct 23 (Reuters) - Today we shine a light on a study that suggests just how misguided and potentially ...

The findings run counter to updated guidance issued in January 2025 by the U.S. Centers for Disease Control and Prevention ...

Ending routine vaccination for hepatitis B at birth, as the health secretary has recommended, would increase the number of ...

For the first time, many people living with chronic hepatitis B may have a functional cure at hand. The US Food and Drug ...

Arbutus Biopharma (ABUS) said Thursday the US Food and Drug Administration lifted a clinical hold on its AB-101 treatment for hepatitis B, letting the company run further trials o ...

The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill ...

A new study projects that delaying or omitting the hepatitis B shot at birth could increase chronic infections among children by 83%. Under the direction of Health Secretary RFK Jr., the CDC ended its ...

GSK received FDA approval for Hibsago, an antisense oligonucleotide injection used with existing antiviral therapy to treat ...